insights_auto
Hvorfor har GILD gĂ¥tt opp? 2,49%?
GĂ¥ mer i dybdenchevron_right
GILD:NASDAQ
Gilead Sciences, Inc
157,37Â USD
arrow_upward
+2,49%(+3,83) 1Â D
157,02Â USD
arrow_downward
−0,22% (−0,35)todayFør børsĂ¥pning
Stengt: 15. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GILD …
Ă…pne
156,39Â USD
Høy
160,51Â USD
Lav
156,02Â USD
Markedsverdi
195,13Â mrd.
Snittvolum
5,67Â mill.
Volum
1,68k
Utbytte
2,08Â %
Kvartalsvis utbytte
0,82Â USD
Første dato etter utbytte
15. sep. 2026
52 u høy
160,51Â USD
52Â u lav
114,02Â USD
EPS
−2,66 USD
Beta
0,32
UtestĂ¥ende aksjer
1,24Â mrd.
Antall ansatte
17k
Ă…pne
156,39Â USD
Høy
160,51Â USD
Lav
156,02Â USD
Markedsverdi
195,13Â mrd.
Snittvolum
5,67Â mill.
Volum
1,68k
Utbytte
2,08Â %
Kvartalsvis utbytte
0,82Â USD
Første dato etter utbytte
15. sep. 2026
52 u høy
160,51Â USD
52Â u lav
114,02Â USD
EPS
−2,66 USD
Beta
0,32
UtestĂ¥ende aksjer
1,24Â mrd.
Antall ansatte
17k
Nyhetssaker
Fra nettkilder og nyhetspartnere
MarketBeat
·
for 19 minutter siden
Ninety One UK Ltd Buys New Shares in Gilead Sciences, Inc. $GILD
Kalkine Media
·
for 1 time siden
Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation?
Investing.com Nigeria
·
for 5 timer siden
Form 144 GILEAD SCIENCES For: 16 October By Investing.com
Zacks
·
for 11 timer siden
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Om Gilead Sciences, Inc
Administrerende direktørDaniel O'Day
Ansatte17k
Grunnlagt22. juni 1987
HovedkontorFoster City, California, USA
Sektor-
Nettstedgilead.com